Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
BD Diagnostics and Diagenode announced the European-only launch of the Diagenode Bordetella pertussis/parapertussis real-time PCR kit for use on the BD Max system. The kit has been CE-marked and validated to run on the BD Max system using the BD Max ExK DNA-1 extraction kit, an open-system reagent. BD Diagnostics, 800-675-0938 Diagenode, 862-209-4680
PolyScience’s performance programmable circulating baths make it simple to create and run multi-step ramp and soak temperature programs as well as frequently used single temperature testing protocols. The baths have an icon-driven touchscreen display that makes it easy to select and set operational parameters. A built-in electronic keypad speeds and simplifies the entry of text and numerical values. Available in refrigerating/heating and heat-only models, PolyScience performance programmable circulating baths control bath temperatures from −40°C to 200°C with ±0.005°C stability and
Qiagen announced a partnership with Exosome Diagnostics to develop and commercialize high-performance biofluid sample preparation kits for the processing of nucleic acids from exosomes. Combining Exosome Diagnostics’ platform technology approach with select Qiagen consumables and automation platforms has the potential to allow researchers, drug developers, and medical professionals to take repeated, real-time genetic “snapshots” of disease from patients’ blood, urine, or cerebrospinal fluid without the need for tissue biopsy. Qiagen’s exosome technology-driven kits will offer the ability to work with
Immunetics has received FDA clearance for its BacTx rapid test for bacteria in apheresis platelets. The BacTx system is a colorimetric assay that can detect aerobic, anaerobic, gram-negative, and gram-positive bacteria in a single test. The BacTx assay uses a patented, specific, universal bacterial detection reagent that has been shown to detect wild and cultured bacterial strains. BacTx is intended for use as a point-of-issue test performed at the transfusion site on the day of issue. The BacTx assay can
ELGA Process Water introduces the Medica Pro electrodeionization (EDI) water purification system. The system consistently produces high-purity water at economical running costs for immunochemistry and general chemistry automated clinical analyzers. ELGA’s Pulse technology combined with extended intervals between sanitization reduces maintenance time.
Diagnostic BioSystems’ anti-PIN5 cocktail helps distinguish prostate cancer from benign conditions that mimick cancer. The cocktail works through the combined detection of p504S, p40, and high molecular-weight cytokeratin markers. The markers are particularly relevant in helping to diagnose prostatic intraepithelial neoplasia. The markers also offer utility in difficult cases where tissue may be limited.
Sysmex America has renewed its agreement to distribute Medica’s EasyCell assistant for digital cell image analysis in hematology laboratories. EasyCell uses optical pattern recognition software to automatically locate white cells on a blood smear. It digitally stores, preclassifies, and presents images for review, grouped by cell type, on an LCD display.
Randox Laboratories has received FDA approval for its Acusera immunoassay specialty 1 control for use in U.S. laboratories. The multi-analyte, lyophilized control contains I-25-(OH)2-vitamin D, 25-OH-vitamin D, C peptide, insulin, insulin-like growth factor-1, procalcitonin, parathyroid hormone, anti-thyroglobulin, and anti-thyroperoxidase.
SciGene’s CytoZyme stabilized pepsin is an advanced formulation of pepsin for pretreating tissue samples in nucleic acid probe-based cytogenetic assays, including FISH.
Genomic Health made its Oncotype DX prostate cancer test available recently after a presentation of a positive clinical validation study by the University of California, San Francisco, at this year’s American Urological Association annual meeting.
